Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sesen’s Phase III Bladder Cancer Results Spark Mixed Reactions

Executive Summary

The updated data are in line with prior interim readouts but nonetheless triggered strong reactions. One analyst slashed their peak sales forecast for Vicinium, while another talked up the likelihood of rapid commercial adoption of the fusion protein-drug conjugate.

You may also be interested in...



Where Next For Sesen Bio’s Bladder Cancer Therapy Vicineum?

A complete response letter from the FDA has dashed Sesen Bio’s hopes of being first with a therapy for treating BCG-unresponsive non-muscle invasive bladder cancer. Its CEO says the FDA’s move may reflect heightened ‘pressure’ regulator is under.

Zydus Cadila Joins IO Therapy League With XOMA Tie-up

Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody

Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA

The latest drug development news and highlights from our US FDA Performance Tracker.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC125691

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel